stockrow
Friday 6 November 2026
Export SBFM’s income statement to Excel — free account
Sunshine Biopharma, Inc.
SBFM Healthcare Drug Manufacturers Specialty & Generic
Sunshine Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.3 million, up 4.11% from fiscal 2024.
- Revenue
- −1.56%
- EPS
- +70.9%
- Free cash flow
- +49.4%
Quarter to June 2026, against a year earlier
2.71
0.08
−2.87%
Follow SBFM
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | 4 | 3 |
+8 more TTM periods Free account |
| (21.93%) | (27.33%) | (25.69%) | (24.35%) | ||
| (17.78%) | (21.15%) | (19.71%) | (19.47%) | ||
ROIC |
(26.67%) | (27.08%) | (27.97%) | (27.38%) | |
Return on Tangible Assets |
(22.85%) | (31.10%) | (28.50%) | (27.35%) | |
Average Days of Receivables |
41.67 | 41.25 | 34.78 | 40.64 | |
Free Cash Flow per Share |
(81.06) | (262.73) | (296.51) | (351.07) | |
Free Cash Flow |
(5.54) | (6.44) | (6.17) | (8.00) | |
Capital Expenditures |
(0.18) | (0.73) | (0.84) | (0.88) | |
| Other line items | |||||
Cash ROIC |
(13.41%) | (22.64%) | (19.18%) | (23.89%) | |
Accounts Receivable Turnover |
9.27 | 9.52 | 9.91 | 10.12 | |
Accounts Payable Turnover |
5.11 | 4.70 | 4.29 | 4.86 | |
Inventory Turnover |
1.96 | 1.90 | 1.94 | 2.09 | |
Average Days of Payables |
71.89 | 78.33 | 85.96 | 89.59 | |
Days of Inventory on Hand |
179.59 | 202.06 | 204.46 | 205.30 | |
Tax Rate |
0.00 | 0.01 | 0.00 | (0.08) | |
Research and Development Expense of Revenue |
0.67% | 1.19% | 1.66% | 1.82% | |
Selling, General and Administrative Expense of Revenue |
48.29% | 48.65% | 48.33% | 43.53% | |
Share Based Compensation of Revenue |
0.27% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.92 | 0.95 | 0.89 | 1.19 | |
Depreciation/Fixed assets |
2.17 | 4.05 | 3.73 | 3.20 | |
Capex/Depreciation |
(0.18) | (0.35) | (0.40) | (0.46) | |
Revenue per Share |
517.52 | 1,448.71 | 1,745.47 | 1,637.00 | |
Operating CF per Share |
(78.37) | (232.99) | (256.30) | (312.30) | |
Capex per Share |
(2.69) | (29.75) | (40.21) | (38.77) | |
Capex to Sales |
0.01 | 0.02 | 0.02 | 0.02 |
Columns are period end dates · fundamentals updated 2 Nov 2026